Abstract
Cystic Fibrosis, one of the most common inherited lethal disease among Caucasians, is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. The CFTR protein acts as a gated Cl- channel at the apical membrane of epithelial cells, thereby facilitating proper hydration of mucosal linings. Disease causing mutations in the CFTR protein can affect a variety of steps in the biogenesis of a functional protein including the folding and trafficking of CFTR as well as the channel activity of plasma membrane-localized protein. Therefore, current research is focused on the use of small molecules to not only correct folding defects but also to enhance channel activity of mutant CFTR proteins. This review discusses the current knowledge of the folding, trafficking, and gating defects caused by CFTR mutations, the manner by which these defects are monitored by the cell, as well as the strategies which are currently being utilized to develop and screen for small molecule therapeutics.
Keywords: Cystic fibrosis, chaperones, ER Quality control, correctors, potentiators
Current Chemical Biology
Title: The Use of Small Molecules to Correct Defects in CFTR Folding, Maturation, and Channel Activity
Volume: 3 Issue: 1
Author(s): Meredith F.N. Rosser, Diane E. Grove and Douglas M. Cyr
Affiliation:
Keywords: Cystic fibrosis, chaperones, ER Quality control, correctors, potentiators
Abstract: Cystic Fibrosis, one of the most common inherited lethal disease among Caucasians, is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. The CFTR protein acts as a gated Cl- channel at the apical membrane of epithelial cells, thereby facilitating proper hydration of mucosal linings. Disease causing mutations in the CFTR protein can affect a variety of steps in the biogenesis of a functional protein including the folding and trafficking of CFTR as well as the channel activity of plasma membrane-localized protein. Therefore, current research is focused on the use of small molecules to not only correct folding defects but also to enhance channel activity of mutant CFTR proteins. This review discusses the current knowledge of the folding, trafficking, and gating defects caused by CFTR mutations, the manner by which these defects are monitored by the cell, as well as the strategies which are currently being utilized to develop and screen for small molecule therapeutics.
Export Options
About this article
Cite this article as:
Rosser F.N. Meredith, Grove E. Diane and Cyr M. Douglas, The Use of Small Molecules to Correct Defects in CFTR Folding, Maturation, and Channel Activity, Current Chemical Biology 2009; 3 (1) . https://dx.doi.org/10.2174/2212796810903010100
DOI https://dx.doi.org/10.2174/2212796810903010100 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Metabolic Study of Benzamidenafil using Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry
Current Pharmaceutical Analysis Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design Inhibitors of Cytosolic Phospholipase A2α as Potential Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Gene Therapy for Type I Glycogen Storage Diseases
Current Gene Therapy Efficacy of Methylphenidate for Internet Gaming Disorder and Internet Addiction in Patients with Attention-Deficit/Hyperactivity Disorder
Current Pharmaceutical Design Involvement of the Endocannabinoid System in Motor Disorders
Current Medicinal Chemistry - Central Nervous System Agents Stem Cell and Tissue Engineering Therapies for Ocular Regeneration
Current Stem Cell Research & Therapy Type I Collagen and Collagen Mimetics as Angiogenesis Promoting Superpolymers
Current Pharmaceutical Design Severe Asthma: Why do Some Children Not Respond to Treatment?
Current Pediatric Reviews Current and Emerging Pharmacological Therapies for Cushing's Disease
Current Pharmaceutical Design Preface [Hot topic: Protein Misfolding in the Amyloidoses and other Disorders (Guest Editor: David R. Howlett)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents ATP-Binding Cassette Transporters at the Blood-Brain Barrier in Ischaemic Stroke
Current Pharmaceutical Design Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Dementia After Age 75: Survival in Different Severity Stages and Years of Life Lost
Current Alzheimer Research Enhancing Spermatogenesis in Non-obstructive Azoospermia Through Mesenchymal Stem Cell Therapy
Current Stem Cell Research & Therapy Cellular and Physiological Effects of Probiotics and Prebiotics
Mini-Reviews in Medicinal Chemistry <i>In-situ</i> Gels for Brain Delivery: Breaching the Barriers
Current Pharmaceutical Design Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry